Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
about
Antifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsCombination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patientsPharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysisPrimary renal aspergillosis and renal stones in both kidneys associated with hematopoietic stem cell transplant.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.Phase II dose escalation study of caspofungin for invasive Aspergillosis.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelProspective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patientsCaspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Updated guidelines for managing fungal diseases in hematology patients.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Caspofungin: when and how? The microbiologist's view.Efficacy and safety of current drug therapies for invasive aspergillosis.Safety and interactions of new antifungals in stem cell transplant recipients.A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, AsHigh-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events.Current status of antifungal resistance and its impact on clinical practice.Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.Treatment principles for the management of mold infections.Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.New pharmacological opportunities for the treatment of invasive mould diseases.Warfarin treatment and antifungal agent caspofungin for severe fungal infection in a patient previously treated with radiotherapy for oropharyngeal cancer.Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European OrganizationEradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia.Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis.Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence.
P2860
Q28080147-BE9307E6-5512-483F-8CBE-BFC01CBCABE7Q28727508-B4AA68A7-2B54-4C8C-83AE-A230EF3AA482Q33573788-CA7BF6B9-4E4E-4EBC-8779-651AE79596C9Q33696043-D66DC374-0B7D-4CE7-9256-C1B27F8B9925Q34322081-EB7861AA-DB54-40E0-A78F-7602A1E0E303Q34501108-1E7137D5-4C0E-4BE2-AFEA-E39EAB5D923BQ34532546-3CEC6EF5-693E-46F2-9323-C020419EA6CBQ34543970-AF6BEA97-2008-4750-B987-8E0FAC603D79Q35598439-A79378D3-F419-48AD-837C-9FE4264E1034Q35666627-B5250D4B-380D-421B-8B58-53A5161BDAB2Q35807013-7DCA2669-E329-4DE0-9A06-F25F8A540D54Q35958060-7AC3B2D1-33B1-42B5-9B50-C53FB5FD8C17Q36948094-60393159-1C76-4D7F-A7DA-90038071C933Q37469829-AD12C79B-8B9F-45A8-AA2F-CE2EA0175066Q37785548-19391B74-3223-43A7-9965-CE30722EF5E3Q37816399-43920119-87E9-462B-AADF-0D695E5C61C7Q37888750-C493E09C-15DB-4E32-91A1-9A9AF9E9BAC7Q37944001-0CC0CD1D-D8E2-49D5-98EA-02F198E73392Q38036740-681B3EDF-158D-43C7-932E-E25C329A0A7FQ38049498-3917FC8A-21C5-4DC3-ADCD-A106DF5364F6Q38173720-8400ABB0-559A-46B2-A279-2243A74A38A9Q38205859-F2C65DDD-AA0A-4073-92F5-09B04F6D4D70Q38221844-5CFB0649-3098-485E-A438-13959DAFC39FQ38265845-0F133A5C-8880-4720-AD85-8D9749ACF192Q38284463-401DA7BC-8E01-413A-B1AE-558EB18535A0Q38284468-754CA3AB-CEB5-4E74-A7D0-10A9C2427F9DQ38586680-7710ADF8-0E76-419A-8F23-EE4B9DE9954DQ38681635-12AD9EFA-F3D4-4EC8-9615-4D07A8BC2A6CQ38871233-C7579785-6A15-478A-88FC-6439BC1D2FB1Q39037978-B8ACCC19-6A50-4252-8A4C-40F906F051C4Q39127825-4E28A08F-B879-4779-A96B-610C2CC695EDQ39196802-6086F25C-A9B5-4606-82D7-E5A2FC7FFA4FQ40045642-984AAA10-D711-4630-8B28-1B4905B2FC44Q40273481-976BA4FF-722B-4EE9-9718-8C7DF143F59FQ40797535-35B3FA0D-03F9-450D-854C-E308F5554B30Q41441699-0A27FC2F-296E-4A2B-8D07-DEE44AFD81BDQ41653776-E04674D7-C99D-4F43-A933-0701488E7CF3Q42038850-1C209617-70C8-4456-9A3D-359E0F6C7A01Q43975147-9E32CA9B-F7BA-4FB0-B139-7473F336D3B5Q47697132-18084A11-AAFC-451F-8595-88CF69532E22
P2860
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@en
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@nl
type
label
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@en
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@nl
prefLabel
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@en
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@nl
P2093
P2860
P356
P1476
Caspofungin first-line therapy ...... and Treatment of Cancer study.
@en
P2093
A J Ullmann
J Maertens
M Paesmans
M Shivaprakash
P2860
P2888
P304
P356
10.1038/BMT.2009.334
P407
P577
2010-01-11T00:00:00Z
P5875
P6179
1044044731